Search tips
Search criteria

Results 1-21 (21)

Clipboard (0)

Select a Filter Below

Year of Publication
1.  Advanced Therapy Medicinal Products – a Multiple Challenge 
PMCID: PMC3901633  PMID: 24474887
5.  Tissue Banking and Transfusion Medicine – a Suitable Cooperation Model 
PMCID: PMC3267996  PMID: 22407058
7.  Unexpected Hypotensive Events during Preparatory Plasmaphereses 
PMCID: PMC4264517  PMID: 25538542
8.  All Information Is Not Equal: Using the Literature Databases PubMed and The Cochrane Library for Identifying the Evidence on Granulocyte Transfusion Therapy 
To be able to take well-informed decisions or carry out sound research, clinicians and researchers alike require specific information seeking skills matching their respective information needs. Biomedical information is traditionally available via different literature databases. This article gives an introduction to two diverging sources, PubMed (23 million references) and The Cochrane Library (800,000 references), both of which offer sophisticated instruments for searching an increasing amount of medical publications of varied quality and ambition. Whereas PubMed as an unfiltered source of primary literature comprises all different kinds of publication types occurring in academic journals, The Cochrane Library is a pre-filtered source which offers access to either synthesized publication types or critically appraised and carefully selected references. A search approach has to be carried out deliberately and requires a good knowledge on the scope and features of the databases as well as on the ability to build a search strategy in a structured way. We present a specific and a sensitive search approach, making use of both databases within two application case scenarios in order to identify the evidence on granulocyte transfusions for infections in adult patients with neutropenia.
PMCID: PMC4264499  PMID: 25538539
Databases, bibliographic; PubMed; The Cochrane Library; Information seeking behavior; Evidence-based medicine
10.  Quality of Cell Products: Authenticity, Identity, Genomic Stability and Status of Differentiation 
Cellular therapies that either use modifications of a patient's own cells or allogeneic cell lines are becoming in vogue. Besides the technical issues of optimal isolation, cultivation and modification, quality control of the generated cellular products are increasingly being considered to be more important. This is not only relevant for the cell's therapeutic application but also for cell science in general. Recent changes in editorial policies of respected journals, which now require proof of authenticity when cell lines are used, demonstrate that the subject of the present paper is not a virtual problem at all. In this article we provide 2 examples of contaminated cell lines followed by a review of the recent developments used to verify cell lines, stem cells and modifications of autologous cells. With relative simple techniques one can now prove the authenticity and the quality of the cellular material of interest and therefore improve the scientific basis for the development of cells for therapeutic applications. The future of advanced cellular therapies will require production and characterization of cells under GMP and GLP conditions, which include proof of identity, safety and functionality and absence of contamination.
PMCID: PMC2914413  PMID: 20737047
Primary human cells; Cross-contamination; Cell identity; DNA typing; Karyotype
11.  Farewell to Prof. Dr. Dr. Walter Sibrowski 
PMCID: PMC4086765  PMID: 25053927
12.  Perspectives in Transfusion Medicine and Cellular Therapies 
PMCID: PMC4164064  PMID: 25254017
13.  Current Regulations for the Production of Multipotent Mesenchymal Stromal Cells for Clinical Application 
In this review, the appropriate legislation on the expansion of multipotent mesenchymal stromal cells (MSCs) in Europe is described. The collection of cells and the manufacturing of MSCs are being regulated by European Directives (EUDs). Recently, the Regulation on Advanced Therapies Medicinal Products (ATMPs) is being published, which is of importance for the production of MSCs in Europe, and this legislation is not yet ready, but it is in its final stage. MSCs are currently being used in clinical trials, mostly in academic hospitals, for patients suffering from a wide variety of diseases. Companies (small and medium-sized enterprises) are becoming more and more involved in the production of MSCs for human use, and since marketing authorisation is the scope of the Regulation it was decided to install a Committee on Advanced Therapies (CAT) within European Medicines Agency (EMEA). This CAT will formulate a draft opinion on quality, safety and efficacy of ATMPs and will have an advisory and scientific role for the Committee for Medicinal Products for human use. The aim of this review is to outline the current legislation which is important for the manufacturing of MSCs.
PMCID: PMC3076362  PMID: 21512645
MSC; Regulatory issues; Advanced therapy medicinal products
14.  Allele Frequencies Database 
This review describes a database for the collection, archiving, sorting, searching and display of gene and allele frequencies for immunogenetic genes.
PMCID: PMC4264510  PMID: 25538537
Data management system; HLA; Immunogenetics; KIR
15.  Giving Blood and Enrolling on the Stem Cell Donor Registry: Ranking of Obstacles and Motives in Switzerland 
To obtain a better understanding of factors affecting blood and blood stem cell donation behavior in Switzerland, a series of studies has been performed. In the recent study of this series, which is described here, motivators and barriers in the field of blood and blood stem cell donation were identified.
Web-based survey data from a non-random sample of the Swiss population 2012/2013 (n = 3,153) were used to describe and compare the ranking of motives and obstacles to donate blood and to enroll on the Swiss blood stem cell registry. Wilcoxon rank-sum test and Spearman's rank correlations were used to assess differences and associations between ranks and groups.
The prospect of saving lives and solidarity were the top two motives to donate blood or to enroll on the blood stem cell registry. The top two obstacles to enroll on the blood stem cell registry were lack of general information on blood stem cell donation and on its risks, whereas the top two obstacles to donate blood were the lack of information where and when to donate and deferral of or exclusion from blood donation.
Classical altruistic motives are top drivers for giving blood as well as registering for blood stem cell donation. Recruitment campaigns should focus on these motivators. Similarities in motivational factors as well as in obstacles regarding blood and blood stem cell donation can be found.
PMCID: PMC4164091  PMID: 25254022
Blood donation; Blood stem cell donation; Donor motivation
20.  Cumulative effect in transfusion related acute lung injury 
Saudi Journal of Anaesthesia  2012;6(3):313-314.
PMCID: PMC3498686  PMID: 23162421

Results 1-21 (21)